MMQCI'S BLOG
Decoding Leukemia: How NPM1 and PML-RARA Drive Diagnosis and Treatment in AML
Tue, Dec 16th, 2025 3:11 pm
Understanding the molecular drivers of acute myeloid leukemia (AML) has transformed how clinicians diagnose, classify, and treat this complex disease. Two of the most informative genetic alterations—NPM1 mutations and the PML-RARA translocation—play a central role in defining AML subtypes, guiding therapy decisions, and predicting patient outcomes.
Quantitative External Quality Controls for Leukemia – Vital Overseers of Blood Cancer Assay Performance
Jan 15th, 2025
Leukemias are a relatively common set of blood cancers, with close to half a million cases diagnosed worldwide every year. An increase in the availability of diagnostic assays, and advances in leukemia treatments, have overall increased remission...
Read more »
Quality Controls: The Unsung Hero of Molecular Diagnostics
Jun 6th, 2024
Molecular diagnostics has emerged as a cornerstone for disease diagnosis, treatment guidance, and patient management. The ability of molecular assays to detect genetic alterations and identify specific pathogens plays a critical role in shaping...
Read more »
You want to run what? 3 Different Perspectives on Using Quality Controls
Apr 16th, 2024
The College of American Pathologists (CAP) Accreditation Program Molecular Pathology Checklist (v. 08.24.2023) defines controls as “surrogates for patient specimens to monitor the ongoing performance of the entire analytic process in every run.”
Read more »